Characterization and Partial Purification of a Leucine Aminopeptidase from Fasciola hepatica

1998 ◽  
Vol 84 (1) ◽  
pp. 1 ◽  
Author(s):  
Daniel Costa ◽  
Fernando Goni ◽  
Carlos Carmona
2017 ◽  
Vol 33 (5) ◽  
pp. 2676-2680 ◽  
Author(s):  
Taghreed U. Mohammd ◽  
Layla O. Farhan ◽  
Ashgan S. Dawood ◽  
Bushra F. Hasan

2007 ◽  
Vol 15 (1) ◽  
pp. 95-100 ◽  
Author(s):  
A. Marcilla ◽  
J. E. De la Rubia ◽  
J. Sotillo ◽  
D. Bernal ◽  
C. Carmona ◽  
...  

ABSTRACT The liver fluke Fasciola hepatica parasitizes humans and ruminant livestock worldwide, and it is now being considered a reemerging zoonotic disease, especially in areas in which it is endemic, such as South America. This study investigates the immune response to excretory and secretory products produced by F. hepatica in a group of patients from the Peruvian Altiplano, where the disease is highly endemic. Using a proteomic approach and immunoblotting techniques, we have identified the enzymes leucine aminopeptidase (LAP) and phosphoenolpyruvate carboxykinase as immunodominant antigens recognized by sera from fasciolosis patients. An indirect enzyme-linked immunosorbent assay using recombinant LAP as the antigen was developed to check sera from individuals of this region. Our results demonstrate that LAP produces a specific and strong reaction, suggesting its potential use in the serologic diagnosis of F. hepatica infections in humans.


2012 ◽  
Vol 9 (4) ◽  
pp. 689-694
Author(s):  
Baghdad Science Journal

Leucine aminopepotidase (LAP)[EC:3.4.11.1] activity has been assayed in (50) serum samples of patients with diabeties naphrophathy D.N (non-insulin dependent diabetic (NIDD) , and (50)serum sample of healthy individuals without any clinically detectable diseases have been as control group. The aim of this study is to measure leucine aminopeptidase activity and partially purifying the enzyme from sera of patients with diabetes nephropathy The results of this study revealed that Leucine aminopeptidase (LAP) activity of nephropathy patient’s serum shows a high signifiacant increase (p < 0.001) compared to that of the healthy subjects.LAP was purified from the serum of patients with diabetes nephropathy by dialysis and gel filtration (Sephadex G-25) (fine ) (20 × 1.5 cm ) .A (1.37) fold purification of serum LAP from patients serum with diabetic nephropathy was achieved by using dialysis and this enzyme showed single grade increased to (8.33) fold by using gel filtration Abbreviation: Leucine aminopeptidase=LAP, Diabetes Nephropathy= D.N, Non- Insulin dependent diabetic= NIDD.


1977 ◽  
Vol 63 (3) ◽  
pp. 430 ◽  
Author(s):  
George V. Hillyer ◽  
Noemi Santiago de Weil

Vaccine ◽  
2011 ◽  
Vol 29 (48) ◽  
pp. 9057-9063 ◽  
Author(s):  
Gabriela Maggioli ◽  
Daniel Acosta ◽  
Fernando Silveira ◽  
Silvina Rossi ◽  
Sheila Giacaman ◽  
...  

2014 ◽  
Vol 90 (1) ◽  
pp. 7-13 ◽  
Author(s):  
K. Hernández-Guzmán ◽  
A. Sahagún-Ruiz ◽  
A.J. Vallecillo ◽  
I. Cruz-Mendoza ◽  
H. Quiroz-Romero

AbstractLeucine aminopeptidase (LAP) and cathepsin L1 (CL1) are important enzymes for the pathogenesis and physiology ofFasciola hepatica. These enzymes were analysedin silicoto design a chimeric protein containing the most antigenic sequences of LAP (GenBank; AAV59016.1; amino acids 192–281) and CL1 (GenBank CAC12806.1; amino acids 173–309). The cloned 681-bp chimeric fragment (rFhLAP-CL1) contains 270 bp from LAP and 411 bp from CL1, comprising three epitopes, DGRVVHLKY (amino acids 54–62) from LAP, VTGYYTVHSGSEVELKNLV (amino acids 119–137) and YQSQTCLPF (amino acids 161–169) from CL1. The ~25 kDa rFhLAP-CL1 chimeric protein was expressed from the pET15b plasmid in the Rosetta (DE3)Escherichia colistrain. The chimeric protein rFhLAP-CL1, which showed antigenic and immunogenic properties, was recognized in Western blot assays usingF. hepatica-positive bovine sera, and induced strong, specific antibody responses following immunization in rabbits. The newly generated chimeric protein may be used as a diagnostic tool for detection of antibodies againstF. hepaticain bovine sera and as an immunogen to induce protection against bovine fasciolosis.


2016 ◽  
Vol 91 (2) ◽  
pp. 99-109 ◽  
Author(s):  
C. Carmona ◽  
J.F. Tort

AbstractFasciolosis caused byFasciola hepaticaseverely affects the efficiency of livestock production systems worldwide. In addition to the economic impact inflicted on livestock farmers, fasciolosis is an emergent zoonosis. This review emphasizes different aspects of the disease in South America. Available data on epidemiology in bovines and ovines in different countries, as well as a growing body of information on other domestic and wildlife definitive hosts, are summarized. The issue of drug resistance that compromises the long-term sustainability of current pharmacological strategies is examined from a regional perspective. Finally, efforts to develop a single-antigen recombinant vaccine in ruminants are reviewed, focusing on the cases of leucine aminopeptidase or thioredoxin glutathione reductase.


Sign in / Sign up

Export Citation Format

Share Document